Picture of Essex Bio-Technology logo

1061 — Essex Bio-Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Brief: Essex Bio-Technology Updates On U.S. FDA First Phase 3 Clinical Trial Relating To Dry Eye Disease

July 19 (Reuters) - Essex Bio-Technology Ltd  1061.HK :
    * UPDATES ON U.S. FDA FIRST PHASE 3 CLINICAL TRIAL RELATING
TO DRY
EYE DISEASE
    * ESSEX BIO-INVESTMENT & MITOTECH DISCUSSING ON TAKING U.S.
FDA
PHASE 3 CLINICAL TRIAL OF PRODUCT TO SECOND PHASE 3 CLINICAL
TRIAL
    * POSITIVE TOPLINE DATA ACHIEVED DURING FIRST P3 TRIAL
SHOWING
CLINICALLY RELEVANT SIGNS OF EFFICACY & SAFETY OF PRODUCT

Source text for Eikon:  urn:newsml:reuters.com:*:nHKS63jV4m
Further company coverage:  1061.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Essex Bio-Technology

See all news